These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10965989)

  • 21. Bile acid derived HMG-CoA reductase inhibitors.
    Kramer W; Wess G; Enhsen A; Bock K; Falk E; Hoffmann A; Neckermann G; Gantz D; Schulz S; Nickau L
    Biochim Biophys Acta; 1994 Nov; 1227(3):137-54. PubMed ID: 7986821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
    Del Puppo M; Rauli S; Galli Kienle M
    Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ; Barrett PH; Huff MW
    J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
    Guijarro C; Blanco-Colio LM; Massy ZA; O'Donnell MP; Kasiske BL; Keane WF; Egido J
    Kidney Int Suppl; 1999 Jul; 71():S88-91. PubMed ID: 10412746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
    Ichihara K; Satoh K; Yamamoto A; Hoshi K
    Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():142P-149P. PubMed ID: 10629871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
    Tesfamariam B; Frohlich BH; Gregg RE
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
    Oi S; Haneda T; Osaki J; Kashiwagi Y; Nakamura Y; Kawabe J; Kikuchi K
    Eur J Pharmacol; 1999 Jul; 376(1-2):139-48. PubMed ID: 10440099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
    Sirtori CR
    Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors.
    Humble E; al-Shurbaji A; Lund E; Berglund L
    Biochim Biophys Acta; 1994 Aug; 1214(1):32-8. PubMed ID: 8068726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of substrates and competitive inhibitors on the phosphatase-dependent activation of hepatic hydroxymethylglutaryl CoA reductase.
    Feingold KR; Moser AH
    Arch Biochem Biophys; 1986 Aug; 249(1):46-52. PubMed ID: 3017222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
    Kato T; Tokoro T; Namii Y; Kobayashi T; Hayashi S; Yokoyama I; Morimoto S; Chan M; Giannetti N; Hunt SA
    Transplant Proc; 2000 Mar; 32(2):331-3. PubMed ID: 10715431
    [No Abstract]   [Full Text] [Related]  

  • 33. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
    Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS
    Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity of statins on rat skeletal muscle mitochondria.
    Kaufmann P; Török M; Zahno A; Waldhauser KM; Brecht K; Krähenbühl S
    Cell Mol Life Sci; 2006 Oct; 63(19-20):2415-25. PubMed ID: 17013560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
    Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G
    Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluvastatin cost considerations.
    Garnett WR
    Ann Pharmacother; 1994 Sep; 28(9):1111-2. PubMed ID: 7803895
    [No Abstract]   [Full Text] [Related]  

  • 37. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
    Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
    Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antioxidative effects of fluvastatin, and its major metabolites].
    Nakashima A; Ohtawa M; Masuda N; Morikawa H; Bando T
    Yakugaku Zasshi; 1999 Jan; 119(1):93-9. PubMed ID: 9922713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
    Stalenhoef AF; Stehouwer CD
    Ned Tijdschr Geneeskd; 2000 Feb; 144(7):308-10. PubMed ID: 10707739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
    Roberts WC
    Am J Cardiol; 1997 Jul; 80(1):106-7. PubMed ID: 9205036
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.